Abstract:Context Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma with poor prognosis and high recurrence rates in patients. The development of MCL is largely attributed to cell cycle dysregulation. Cell division cycle 20 (CDC20) is a key member of cell cycle checkpoints, and high expression of CDC20 was reported in a variety of tumors. Few studies have explored the role of CDC20 in MCL. Objective This study was aimed to investigate whether CDC20 could promote cancer progression and the potential of CDC20 to be a therapeutic target in MCL. Design Peripheral blood mononuclear cells (PBMCs) from 18 MCL patients and 7 healthy donors and 5 MCL cell lines (Jeko, Mino, Rec1, Z138, and JVM2) were acquired to detect CDC20 expression. CDC20 inhibitor apcin was used in Z138 to evaluate its antitumor effects in vitro, including cell viability, cell apoptosis, cell cycle, cell migration, and invasion. Possible changes of some related genes were assessed after apcin treatment. Results CDC20 was overexpressed in 94.4% (17/18) of MCL patients and 5 MCL cell lines compared with healthy controls. Cell growth was inhibited, and cell apoptosis was induced in apcin-treated Z138 cells. After 48 h apcin treatment, cell cycle was arrested in the G2/M phase, characterized by an increased number of Z138 cells in this period. The abilities of cell migration and invasion were significantly attenuated with apcin treatment. The expression of cyclinB1, a marker of the G2/M phase, was significantly increased, together with increased Bim expression and decreased Bcl-xL expression in apcin-treated Z138 cells. Conclusions CDC20 might contribute to tumorigenesis in MCL. Further studies should be carried out to determine whether CDC20 inhibitors could impede tumor progression in MCL patients. This work was supported by grants from the Natural Science Foundation of Beijing Municipality [7182178]. Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma with poor prognosis and high recurrence rates in patients. The development of MCL is largely attributed to cell cycle dysregulation. Cell division cycle 20 (CDC20) is a key member of cell cycle checkpoints, and high expression of CDC20 was reported in a variety of tumors. Few studies have explored the role of CDC20 in MCL. This study was aimed to investigate whether CDC20 could promote cancer progression and the potential of CDC20 to be a therapeutic target in MCL. Peripheral blood mononuclear cells (PBMCs) from 18 MCL patients and 7 healthy donors and 5 MCL cell lines (Jeko, Mino, Rec1, Z138, and JVM2) were acquired to detect CDC20 expression. CDC20 inhibitor apcin was used in Z138 to evaluate its antitumor effects in vitro, including cell viability, cell apoptosis, cell cycle, cell migration, and invasion. Possible changes of some related genes were assessed after apcin treatment. CDC20 was overexpressed in 94.4% (17/18) of MCL patients and 5 MCL cell lines compared with healthy controls. Cell growth was inhibited, and cell apoptosis was induced in apcin-treated Z138 cells. After 48 h apcin treatment, cell cycle was arrested in the G2/M phase, characterized by an increased number of Z138 cells in this period. The abilities of cell migration and invasion were significantly attenuated with apcin treatment. The expression of cyclinB1, a marker of the G2/M phase, was significantly increased, together with increased Bim expression and decreased Bcl-xL expression in apcin-treated Z138 cells. CDC20 might contribute to tumorigenesis in MCL. Further studies should be carried out to determine whether CDC20 inhibitors could impede tumor progression in MCL patients. This work was supported by grants from the Natural Science Foundation of Beijing Municipality [7182178].

MDM2-P53 Signaling Pathway-Mediated Upregulation of CDC20 Promotes Progression of Human Diffuse Large B-Cell Lymphoma

MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B cell lymphoma patients treated with rituximab CHOP immunochemotherapy: a report …

Dysregulated CXCR4 Expression Promotes Lymphoma Cell Survival and Independently Predicts Disease Progression in Germinal Center B-cell-like Diffuse Large B-cell Lymphoma.

p53 directly downregulates the expression of CDC20 to exert anti-tumor activity in mantle cell lymphoma

Upregulation of USP25 promotes progression of human diffuse large B-cell lymphoma through blocking the ubiquitinated degradation of MDM2

CCDC50, an Essential Driver Involved in Tumorigenesis, is a Potential Severity Marker of Diffuse Large B Cell Lymphoma

Progress in deciphering the role of p53 in diffuse large B-cell lymphoma: mechanisms and therapeutic targets

CDC20 Regulates the Cell Proliferation and Radiosensitivity of P53 Mutant HCC Cells Through the Bcl-2/Bax Pathway.

Gene expression profiles analysis identifies a novel two-gene signature to predict overall survival in diffuse large B-cell lymphoma

IDO1 plays a tumor-promoting role via MDM2-mediated suppression of the p53 pathway in diffuse large B-cell lymphoma

The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma.

Genetic characteristics involving the PD-1/PD-L1/L2 and CD73/A2aR axes and the immunosuppressive microenvironment in DLBCL

The Ubiquitin Ligase MDM2 Sustains STAT5 Stability to Control T Cell-Mediated Antitumor Immunity

Low NDRG2, regulated by the MYC/MIZ-1 complex and methylation, predicts poor outcomes in DLBCL patients

Comprehensive Analysis of TP53 Mutation Characteristics and Identification of Patients with Inferior Prognosis and Enhanced Immune Escape in Diffuse Large B Cell Lymphoma

Single-cell RNA sequencing in double-hit lymphoma: IMPDH2 induces the progression of lymphoma by activating the PI3K/AKT/mTOR signaling pathway

MCL-363: Overexpression of CDC20 Promotes Cancer Progression in Mantle Cell Lymphoma

CDK12 activates MYC to repress miR-28-5p/EZH2 and amplifies tonic BCR signaling to promote the development of diffuse large B-cell lymphoma

Inhibition of CDC20 Suppressed the Development and Progression of Mantle Cell Lymphoma

[Expression of Cdc7 and Mcm2 As a Marker for Proliferation and Prognosis in Diffuse Large B Cell Lymphoma].

A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality with BTK or MDM2-P53 Inhibitor in Diffuse Large B-Cell Lymphoma.